← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Inova Health Care Services
Fairfax, VA
$10,446,202
Total funding
14
Grants
Funding over time
peak $1.7M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,054,764 · 11
FDA$698,249 · 1
DOD$693,189 · 2
By mechanism
R01$6,509,347 · 5
K23$2,318,520 · 3
R18$698,249 · 1
—$693,189 · 2
R21$206,897 · 1
R13$20,000 · 2
Investigators at Inova Health Care Services
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Phenotyping Net Immune State with MicroRNAs in Cardiac Transplantation$804,438
R01 · FY2025 · HL
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention$582,131
R01 · FY2025 · HD
Computational modeling of tumor burden by CT to advance cancer therapeutics$579,655
R01 · FY2016 · CA
Computational modeling of tumor burden by CT to advance cancer therapeutics$573,026
R01 · FY2018 · CA
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention$571,020
R01 · FY2023 · HD
Computational modeling of tumor burden by CT to advance cancer therapeutics$558,237
R01 · FY2020 · CA
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention$556,408
R01 · FY2024 · HD
Computational modeling of tumor burden by CT to advance cancer therapeutics$556,187
R01 · FY2019 · CA
The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community$499,244
R18 · FY2021 · FD
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization$418,800
R01 · FY2020 · HL
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization$399,760
R01 · FY2021 · HL
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization$388,080
R01 · FY2022 · HL
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization$387,840
R01 · FY2023 · HL
THERAPEUTIC ERADICATION OF DCIS PROGENITOR CELLS$381,479
· FY2010 · Department of Defense
CAN WE AVOID ANTICOAGULATION IN EXTRACORPOREAL LIFE SUPPORT (ECLS)? THE IMPACT OF ANTICOAGULATION MONITORING AND ADMINISTRATION PRACTICES$311,710
· FY2022 · Defense Health Agency
The Scientific Value of Premature Infant Biospecimens Collection$206,897
R21 · FY2024 · GM
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation$185,760
K23 · FY2022 · HL
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation$185,760
K23 · FY2021 · HL
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation$185,760
K23 · FY2020 · HL
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation$184,680
K23 · FY2024 · HL